Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 5/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.36 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2573169 | 0.83 | NCEH1 (0.41) | — | |
| SCHEMBL14575605 | 0.82 | BCL6 (0.35) | EGLN1KDM4E | |
| SCHEMBL2575235 | 0.82 | HSP90AA1 (0.46) | RAB9ANPC1GAAHPGDSMN1; SMN2 | |
| SCHEMBL2560122 | 0.78 | PORCN (0.42) | EGLN1KDM4EMEN1KMT2A | |
| SCHEMBL2566123 | 0.76 | ALDH1A1 (0.51) | RAB9ANPC1GAAHPGDSMN1; SMN2 | |
| SCHEMBL2564810 | 0.76 | EGLN1 (0.36) | HPGDEGLN1KDM4EMEN1KMT2A | |
| SCHEMBL16005608 | 0.76 | EGLN1 (0.37) | HPGDEGLN1KDM4EMEN1KMT2A | |
| SCHEMBL2575187 | 0.76 | ALKBH1 (0.41) | RAB9ANPC1SMN1; SMN2EGLN1ALKBH1 | |
| SCHEMBL2572995 | 0.76 | EGLN1 (0.41) | RAB9ANPC1HPGDSMN1; SMN2EGLN1 | |
| SCHEMBL2564568 | 0.74 | MEN1 (0.47) | RAB9ANPC1GAAHPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | claimed |
| US-9006433-B2 | Substituted pyrimidines | MERCK SHARP & DOHME CORP. (US) | 2015-04-14 | — | — | US | claimed |
| EP-2560655-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2013-02-27 | — | — | EP | claimed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | claimed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| WO-2011133444-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | claimed |
| EP-2560655-B1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2560655-A1 | SUBSTITUTED PYRIMIDINES | Merck Sharp & Dohme Corp. (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME LLC | 2013-01-17 | — | — | US | disclosed |
| WO-2011130908-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2011133444-A1 | SUBSTITUTED PYRIMIDINES | MERCK SHARP & DOHME CORP. (US) | 2011-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018053-A1 | SUBSTITUTED PYRIMIDINES | HIF1AN, HIF1A, EGLN3 | RAB9A 4227/4885NPC1 3276/4885TAAR1 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.